Is NCT05591027 recruiting in Portland, OR?

Yes, NCT05591027 is currently recruiting participants at its Portland, OR location. This mild cognitive impairment clinical trial is actively enrolling qualified participants.

How do I join the mild cognitive impairment clinical trial in Portland?

To join this clinical trial in Portland, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Portland clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Mild Cognitive Impairment Clinical Trial in Portland, OR

About This Mild Cognitive Impairment Study in Portland

This clinical trial is focused on determining whether biological signatures of target engagement by a Centella asiatica water extract product administered orally for 6 weeks can be measured in comparison to placebo. This study will also assess the safety and tolerability of the Centella asiatica water extract product.

Sponsor: Oregon Health and Science University

Who Can Participate

Inclusion Criteria

Age 60-85, male and female

Sufficient English language skills to complete all tests

Sufficient vision and hearing to complete all tests

No known allergies to Centella asiatica

Absence of significant depression symptoms (Geriatric Depression Scale-15 score of \< 5).

Total score of \<2 on the suicidal ideation subscale (measures 3, 7, 11, 12 and 14) of the Geriatric Depression Scale.

Body Mass Index (BMI) greater than 17 and less than 35 at screening

General health status that will not interfere with the ability to complete the study

Willingness to discontinue all botanical dietary supplements for one week prior to and during the study.

Willingness to undertake multiple MRI scans

Meet the National Institute of Aging - Alzheimer's Association core clinical criteria for MCI or probable AD dementia with a Clinical Dementia Rating score of 0.5-1 and Mini Mental State Examination score of 20-28 at screening and baseline

Participants who report a history of participative memory decline with gradual onset and slow progression over the last one year before screening MUST be corroborated by an informant.

Participants on acetylcholinesterase inhibitor or memantine therapy for AD must be on a stable dose for at least 12 weeks prior to baseline visit.

Participants must have an identified caregiver/study partner that can accompany participant to all study visits.

Exclusion Criteria

Current smoking, alcohol, or substance abuse according to DSM-V criteria

Women who are pregnant, planning to become pregnant, or breastfeeding

Men who are actively trying to conceive a child or planning to within three months of study completion

Severe aversion to venipuncture

Abnormal labs indicating asymptomatic and untreated urinary tract infection

Cancer within the last five years, with the exception of localized prostate cancer (Gleason Grade \< 3) and non-metastatic skin cancers

Comorbid conditions such as type I diabetes mellitus, poorly controlled type II diabetes mellitus (HbA1c \> 7%), kidney failure, liver failure, hepatitis, blood disorders, clinical symptomatic orthostatic hypotension, and unstable or significantly symptomatic cardiovascular disease

Significant disease of the Central Nervous System (CNS) such as brain tumor, seizure disorder, subdural hematoma, cranial arteritis, or clinically significant stroke

Major depression, schizophrenia, or other major psychiatric disorder defined by DSM-V criteria

Medications: anti-epileptics, sedatives, amitriptyline, anticoagulants (e.g., warfarin), investigational drugs used within five half-lives of baseline visit, systemic corticosteroids, neuroleptics, anti-Parkinsonian agents, narcotic analgesics, nicotine (tobacco, patches, gum, lozenges, etc.), Cannabis sativa (herb or edibles), beta blockers and anti-depressant medications that have not been at stable dosage for two months (including SSRIs, SNRIs)

Non-Alzheimer dementia such as vascular dementia, normal pressure hydrocephalus, or Parkinson's disease

MMSE score of \< 20 or \> 28

Unwilling to maintain stable dosage of AD medications throughout study duration

Unwilling to maintain stable dosage of intervention throughout the course of the study

Contraindications to Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopic Imaging (MRSI) scans (some metal implants, pacemakers, claustrophobia)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Portland?

Yes, this clinical trial (NCT05591027) has an active research site in Portland, OR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Mild Cognitive Impairment Treatment Options in Portland, OR

If you're searching for mild cognitive impairment treatment options in Portland, OR, this clinical trial (NCT05591027) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Portland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced mild cognitive impairment specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all mild cognitive impairment clinical trials near you to find additional studies recruiting in your area.

Mild Cognitive Impairment Clinical Trial in Portland, OR

Expert Care in Portland

IRB Approved

No-Cost Care

Apply for This Portland Location

Why Participate?

Simple Process